Stay updated on Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Revision: v3.3.4 updates the page from v3.3.3; no study content or eligibility details appear affected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:44:16.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The page now includes a dedicated Locations section listing study sites in Illinois, Indiana, Iowa, Minnesota, and Wisconsin. The separate Illinois Locations entry and related footer label have been removed as part of this update.
    Difference
    0.6%
    Check dated 2025-12-23T20:22:27.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.2.0 to v3.3.2, a minor administrative change that does not affect study content or details. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T11:48:56.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The government funding notice at the bottom of the page was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-18T07:14:07.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    No significant changes detected in core study information (enrollment, eligibility, sites, dosing, or outcomes). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T21:20:28.000Z thumbnail image
  8. Check
    103 days ago
    Change Detected
    Summary
    Major addition of a government funding notice and upgrade to v3.2.0, replacing v3.1.0; references to operating status and status inquiries are now present.
    Difference
    3%
    Check dated 2025-10-06T05:51:27.000Z thumbnail image

Stay in the know with updates to Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.